Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

• Sponsor: ViiV Healthcare (Industry)
• Overall Status: Completed
• CT.gov ID: NCT02478463
• Collaborator: (none)
• Enrollment: 19
• Locations: 2
• Arm: 1
• Actual Duration (Months): 28.8
• Patients Per Site: 9.5
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

Cabotegravir (CAB) long-acting (LA) is a promising candidate for human immunodeficiency virus (HIV) pre exposure prophylaxis (PrEP) due to its potent antiretroviral activity and infrequent dosing requirements. Currently, the CAB concentrations achieved in the anatomical sites associated with sexual HIV transmission following the proposed 600 milligram (mg) intramuscular (IM) PrEP dose are unknown. These data will enhance our understanding of CAB distribution to the anatomical mucosal tissue believed to be relevant to sexual HIV-1 transmission and supplement the data to support future PrEP clinical trial development. The primary objective is to determine the PK concentrations of CAB following LA administration in plasma and in vaginal tissue (VT), cervical tissue (CT), and cervicovaginal fluid (CVF) in healthy women and in rectal tissue (RT) and rectal fluid (RF) in healthy men and women following a single 600 mg IM dose. This will be a Phase 1, open label study in healthy subjects to assess the pharmacokinetics of CAB LA in the plasma and mucosal locations associated with sexual HIV-1 transmission: VT, CT, CVF, RT and RF. The study will consist of a screening period, a 28-day oral lead-in phase at a dose of 30 mg per day followed by a 14-42 day washout period, and a single dose of CAB LA 600 mg as an IM (intragluteal) injection with compartmental pharmacokinetic (PK) sampling for up to 12 weeks. Subjects will return for safety assessments and plasma PK sampling at Week 24 and Week 36 post-injection and undergo a follow-up/withdrawal visit at Week 52 post-injection.

Condition or Disease	Intervention/Treatment	Phase
Infection, Human Immunodeficiency Virus; HIV Infections	Drug: Cabotegravir tablet 30 mg once daily for 28 days.; Drug: Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.	Phase 1

Study Design

• Study Type: Interventional
• Actual Enrollment: 19 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1, Multicompartmental Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers
• Actual Study Start Date: Feb 27, 2017
• Actual Primary Completion Date: Jul 25, 2019
• Actual Study Completion Date: Jul 25, 2019

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Cabotegravir Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.

Drug: Cabotegravir tablet 30 mg once daily for 28 days.; GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237; Drug: Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.; Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL [600 mg] total) IM given once on Day 1 of injection phase

Outcome Measures

Primary Outcome Measures

1. Cabotegravir Concentration in Blood Plasma Following IM Administration [Day 1: Pre-dose and 4 hours; one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36 and 52 post-dose]

   Blood samples were collected to measure cabotegravir concentration in blood plasma following a single 600 mg IM dose at indicated time-points. Evaluable Pharmacokinetic (PK) Plasma Parameter Summary Population comprised of all participants who underwent plasma PK sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and had evaluable PK parameters estimated and no major protocol deviation.

2. Cabotegravir Concentration in Vaginal Tissue Following IM Administration (Female Participants) [One sample on Day 3 and Week 8 post-dose]

   Vaginal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points. Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM) comprised of all participants who underwent sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and have both evaluable PK and evaluable tissues-fluid parameters estimated in vaginal tissue/cervical tissue/cervicovaginal fluid/rectal tissue/rectal fluid.

3. Cabotegravir Concentration in Cervical Tissue Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

   Cervical tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

4. Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

   Cervicovaginal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

5. Cabotegravir Concentration in Rectal Tissue Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

   Rectal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

6. Cabotegravir Concentration in Rectal Fluid Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

   Rectal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.

Secondary Outcome Measures

1. Ratio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants) [One sample on Day 3 and Week 8 post-dose]

   Vaginal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in blood plasma is presented.

2. Ratio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants) [One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose]

   Cervical tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in blood plasma is presented.

3. Ratio of Cabotegravir Concentration in Cervicovaginal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants) [One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose]

   Cervicovaginal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervicovaginal fluid to cabotegravir concentration in blood plasma is presented.

4. Ratio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants) [One sample on Day 3, 8, Weeks 4, 8 and 12]

   Cervical tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in cervicovaginal fluid is presented.

5. Ratio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants) [One sample on Day 3 and Week 8 post-dose]

   Vaginal tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in cervicovaginal fluid is presented.

6. Ratio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration [One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose]

   Rectal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in blood plasma is presented.

7. Ratio of Cabotegravir Concentration in Rectal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

   Rectal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal fluid to cabotegravir concentration in blood plasma is presented.

8. Ratio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Rectal Fluid Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

   Rectal tissue and rectal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in rectal fluid is presented.

9. Maximum Observed Concentration (Cmax) of Cabotegravir in Blood Plasma Following IM Administration [Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose]

   Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

10. Cmax of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervical tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

11. Cmax of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervicovaginal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

12. Cmax of Cabotegravir in Rectal Tissue Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

13. Cmax of Cabotegravir in Rectal Fluid Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

14. Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC[0-last]) for Cabotegravir in Blood Plasma Following IM Administration [Day 1: Pre-dose, 4 hours, One sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose]

    Blood samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

15. AUC(0-last) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervical tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

16. AUC(0-last) of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervicovaginal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

17. AUC(0-last) for Cabotegravir in Rectal Tissue Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

18. AUC(0-last) for Cabotegravir in Rectal Fluid Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

19. Area Under the Concentration Time Curve From Time Zero to Infinity (AUC[0-inf]) for Cabotegravir in Blood Plasma Following IM Administration [Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose]

    Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

20. AUC(0-inf) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervical tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

21. AUC(0-inf) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervicovaginal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

22. AUC(0-inf) for Cabotegravir in Rectal Tissue Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

23. AUC(0-inf) for Cabotegravir in Rectal Fluid Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

24. Area Under the Concentration Time Curve From Time Zero to Week (WK) 4 (AUC[0-WK4]) for Cabotegravir in Blood Plasma Following IM Administration [Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8 and Week 4 post-dose]

    Blood samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

25. AUC(0-WK4) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) [One sample on Days 3, 8 and Week 4 post-dose]

    Cervical tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

26. AUC(0-WK4) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) [One sample on Days 3, 8 and Week 4 post-dose]

    Cervicovaginal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

27. AUC(0-WK4) for Cabotegravir in Rectal Tissue Following IM Administration [One sample on Days 3, 8 and Week 4 post-dose]

    Rectal tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

28. AUC(0-WK4) for Cabotegravir in Rectal Fluid Following IM Administration [One sample on Days 3, 8 and Week 4 post-dose]

    Rectal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

29. Area Under the Concentration Time Curve From Time Zero to Week 8 (AUC[0-WK8]) for Cabotegravir in Blood Plasma Following IM Administration [Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4 and 8 post-dose]

    Blood samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

30. AUC(0-WK8) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4 and 8 post-dose]

    Cervical tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

31. AUC(0-WK8) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4 and 8 post-dose]

    Cervicovaginal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

32. AUC(0-WK8) for Cabotegravir in Rectal Tissue Following IM Administration [One sample on Days 3, 8, Weeks 4 and 8 post-dose]

    Rectal tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

33. AUC(0-WK8) for Cabotegravir in Rectal Fluid Following IM Administration [One sample on Days 3, 8, Weeks 4 and 8 post-dose]

    Rectal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

34. Area Under the Concentration Time Curve From Time Zero to Week 12 (AUC[0-WK12]) for Cabotegravir in Blood Plasma Following IM Administration [Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8 and 12 post-dose]

    Blood samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

35. AUC(0-WK12) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervical tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

36. AUC(0-WK12) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervicovaginal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

37. AUC(0-WK12) for Cabotegravir in Rectal Tissue Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

38. AUC(0-WK12) for Cabotegravir in Rectal Fluid Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

39. Apparent Terminal Phase Half-life (t1/2) of Cabotegravir in Blood Plasma Following IM Administration [Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose]

    Blood samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

40. t1/2 of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervical tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

41. t1/2 of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervicovaginal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

42. t1/2 of Cabotegravir in Rectal Tissue Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

43. t1/2 of Cabotegravir in Rectal Fluid Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.

44. Ratio of AUC(0-last) in Cervical Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervical tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervical tissue to AUC(0-last) in blood plasma is presented.

45. Ratio of AUC(0-last) in Rectal Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal tissue to AUC(0-last) in blood plasma is presented.

46. Ratio of AUC(0-inf) in Cervical Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervical tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervical tissue to AUC(0-inf) in blood plasma is presented.

47. Ratio of AUC(0-inf) in Rectal Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal tissue to AUC(0-inf) in blood plasma is presented.

48. Ratio of AUC(0-Wk4) in Cervical Tissue to AUC(0-Wk4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) [One sample on Days 3, 8 and Week 4 post-dose]

    Cervical tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervical tissue to AUC(0-WK4) in blood plasma is presented.

49. Ratio of AUC(0-Wk 4) in Rectal Tissue to AUC(0-Wk 4) in Blood Plasma for Cabotegravir Following IM Administration [One sample on Days 3, 8 and Week 4 post-dose]

    Rectal tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal tissue to AUC(0-WK4) in blood plasma is presented.

50. Ratio of AUC(0-WK8) in Cervical Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4 and 8 post-dose]

    Cervical tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervical tissue to AUC(0-WK8) in blood plasma is presented.

51. Ratio of AUC(0-WK8) in Rectal Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration [One sample on Days 3, 8, Weeks 4 and 8 post-dose]

    Rectal tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal tissue to AUC(0-WK8) in blood plasma is presented.

52. Ratio of AUC(0-WK12) in Cervical Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervical tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervical tissue to AUC(0-WK12) in blood plasma is presented.

53. Ratio of AUC(0-WK12) in Rectal Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal tissue to AUC(0-WK12) in blood plasma is presented.

54. Ratio of AUC(0-last) in Cervicovaginal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration-female Participants [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervicovaginal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervicovaginal fluid to AUC(0-last) in blood plasma is presented.

55. Ratio of AUC(0-last) in Rectal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal fluid to AUC(0-last) in blood plasma is presented.

56. Ratio of AUC(0-inf) in Cervicovaginal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervicovaginal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervicovaginal fluid to AUC(0-inf) in blood plasma is presented.

57. Ratio of AUC(0-inf) in Rectal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal fluid to AUC(0-inf) in blood plasma is presented.

58. Ratio of AUC(0-WK4) in Cervicovaginal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) [One sample on Days 3, 8 and Week 4 post-dose]

    Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervicovaginal fluid to AUC(0-WK4) in blood plasma is presented.

59. Ratio of AUC(0-WK4) in Rectal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration [One sample on Days 3, 8 and Week 4 post-dose]

    Rectal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal fluid to AUC(0-WK4) in blood plasma is presented.

60. Ratio of AUC(0-WK8) in Cervicovaginal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4 and 8 post-dose]

    Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervicovaginal fluid to AUC(0-WK8) in blood plasma is presented.

61. Ratio of AUC(0-WK8) in Rectal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration [One sample on Days 3, 8, Weeks 4 and 8 post-dose]

    Rectal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal fluid to AUC(0-WK8) in blood plasma is presented.

62. Ratio of AUC(0-WK12) in Cervicovaginal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervicovaginal fluid to AUC(0-WK12) in blood plasma is presented.

63. Ratio of AUC(0-WK12) in Rectal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration [One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose]

    Rectal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal fluid to AUC(0-WK12) in blood plasma is presented.

64. Cabotegravir Concentration in Vaginal Tissue Following Oral Administration (Female Participants) [24 hours post-dose on Day 28]

    Vaginal tissue samples were collected to measure cabotegravir concentration in vaginal tissue following oral 30 mg dose at indicated time-points.

65. Cabotegravir Concentration in Cervical Tissue Following Oral Administration (Female Participants) [24 hours post-dose on Day 28]

    Cervical tissue samples were collected to measure cabotegravir concentration in cervical tissue following oral 30 mg dose at indicated time-points.

66. Cabotegravir Concentration in Cervicovaginal Fluid Following Oral Administration (Female Participants) [24 hours post-dose on Day 28]

    Cervicovaginal fluid samples were collected to measure cabotegravir concentration in cervicovaginal fluid following oral 30 mg dose at indicated time-points.

67. Cabotegravir Concentration in Rectal Tissue Following Oral Administration [24 hours post-dose on Day 28]

    Rectal tissue samples were collected to measure cabotegravir concentration in rectal tissue following oral 30 mg dose at indicated time-points.

68. Cabotegravir Concentration in Rectal Fluid Following Oral Administration [24 hours post-dose on Day 28]

    Rectal fluid samples were collected to measure cabotegravir concentration in rectal fluid following oral 30 mg dose at indicated time-points.

69. Cabotegravir Concentration in Blood Plasma Following Oral Administration [24 hours post-dose on Day 28]

    Blood samples were collected to measure cabotegravir concentration in blood plasma following oral 30 mg dose at indicated time-points.

70. Number of Participants With Any Non-serious Adverse Event (Non-SAE) and Serious Adverse Events (SAE) Following Oral Administration of Cabotegravir [Up to Day 29]

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.

71. Number of Participants With Any Non-SAE and SAE Following IM Administration of Cabotegravir [Up to Week 52]

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.

72. Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Amino Transferase (AST) at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 14 and 29]

    Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

73. Change From Baseline in ALT, ALP and AST at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12]

    Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

74. Change From Baseline in Creatine Kinase at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 14 and 29]

    Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

75. Change From Baseline in Creatine Kinase at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 8 and 12]

    Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

76. Change From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 14 and 29]

    Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

77. Change From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12]

    Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

78. Change From Baseline in Albumin and Total Protein at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 14 and 29]

    Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

79. Change From Baseline in Albumin and Total Protein at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12]

    Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

80. Change From Baseline in Calcium, Glucose, Potassium, Sodium and Urea Enzymatic Colorimetry at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 14 and 29]

    Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and urea enzymatic colorimetry (UEC) following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

81. Change From Baseline in Calcium, Glucose, Potassium, Sodium and UEC at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12]

    Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and UEC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

82. Change From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 14 and 29]

    Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

83. Change From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4 and 8]

    Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

84. Change From Baseline in Total Neutrophil Count at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 14 and 29]

    Blood samples were collected for the assessment of hematology parameter; total neutrophils count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

85. Change From Baseline in Total Neutrophil Count at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12]

    Blood samples were collected for the assessment of hematology parameters; total neutrophil count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

86. Change From Baseline in Platelet Count and White Blood Cell (WBC) Count at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29]

    Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

87. Change From Baseline in Platelet Count and WBC Count at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12]

    Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

88. Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29]

    Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

89. Change From Baseline in Hemoglobin and MCHC at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12]

    Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

90. Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29]

    Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

91. Change From Baseline in MCH at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12]

    Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

92. Change From Baseline in Mean Corpuscle Volume (MCV) at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29]

    Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

93. Change From Baseline in MCV at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12]

    Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

94. Change From Baseline in Hematocrit at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29]

    Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

95. Change From Baseline in Hematocrit at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12]

    Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

96. Change From Baseline in Red Blood Cell (RBC) Count at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29]

    Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

97. Change From Baseline in RBC Count at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12]

    Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

98. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 14 and 29]

    SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

99. Change From Baseline in SBP and DBP at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52]

    SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

100. Change From Baseline in Pulse Rate at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 14 and 29]

     Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

101. Change From Baseline in Pulse Rate at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52]

     Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

102. Change From Baseline in Body Temperature at Indicated Time Points (Oral Dose) [Baseline (Day 1, Pre-dose), Days 14 and 29]

     Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

103. Change From Baseline in Body Temperature at Indicated Time Points (IM Dose) [Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52]

     Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.

104. Number of Participants With Abnormal Urinalysis Parameters Following Oral Administration of Cabotegravir [Up to Day 29]

     Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.

105. Number of Participants With Abnormal Urinalysis Parameters Following IM Administration of Cabotegravir [Up to Week 52]

     Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 55 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Between 18 and 55 years of age inclusive, at the time of signing the informed consent.

• Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.

• A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the medical monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. A single repeat of a procedure or lab parameter is allowed to determine eligibility.

• Body weight >= 40 kilogram (kg) and body mass index (BMI) within the range 18.5 to 35 kg /meter square (inclusive).

• Male or female

• A female subject is eligible to participate if she is pre-menopausal, has an intact uterus and cervix, AND is not pregnant (as confirmed by a negative human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies: a) Non-reproductive potential defined as: Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Documented Bilateral Oophorectomy. b)Reproductive potential and agrees to follow one of the options listed below in the GlaxoSmithKline (GSK) Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication and until at least five terminal half-lives OR until any continuing pharmacologic effect has ended, whichever is longer (can be up to 66 weeks on study) after the last dose of study medication and completion of the follow-up visit. Female subjects desiring pregnancy or foresee that they might wish to become pregnant within 52 weeks of receiving a CAB LA injection must be excluded. All subjects participating in the study must be counseled on safe sexual practices including the use of effective barrier methods to minimize risk of HIV transmission.

• Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.

Exclusion Criteria:

• Liver Function: ALT or AST > upper limit of normal (ULN)

• Total bilirubin >ULN (isolated total bilirubin >ULN is acceptable if total bilirubin is fractionated and direct bilirubin <35%)

• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

• Corrected QT (QTc) Interval: QTc > 450 milliseconds (msec):

NOTES: The QTc is the QT interval corrected for heart rate according to Bazette's formula (QTcB), machine-read or manually over-read. QTcB will be used to determine eligibility for an individual subject. Exclusion criteria for screening electrocardiogram (ECG) (a single repeat is allowed for eligibility determination): Heart rate (<45 and >100 beats per minute (bpm) for males and <50 and >100 bpm for females; QRS duration: >120 msec; QTc interval:

450 msec for males and females

• The subject's systolic blood pressure is outside the range of 90-140 millimeter (mm) mercury (Hg), or diastolic blood pressure is outside the range of 45-90 mmHg.

• History of clinically significant cardiovascular disease including:

Evidence of previous myocardial infarction (pathologic Q waves, S-T segment changes (except early repolarization); History/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PCTA) or any clinically significant cardiac disease; Any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block (2nd degree [type II] or higher), Wolf Parkinson White [WPW] syndrome); Sinus pauses

3 seconds.

• Any significant arrhythmia which, in the opinion of the principal Investigator and GSK Medical Monitor, will interfere with the safety for the individual subject. Non-sustained (>=3 consecutive ventricular ectopic beats) or sustained ventricular tachycardia.

• History of ongoing or clinically relevant seizure disorder within the previous 2 years, including subjects who have required treatment for seizures within this time period. A prior history of seizure, with a seizure free period of at least 2 years, off anti-epileptics, may be considered for enrolment if the investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the medical monitor prior to enrolment

• Use of any concurrent prohibited medications as outlined in protocol

• History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram (g) of alcohol: 12 ounces (360 milliliter [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.

• Inability or unwillingness to comply with lifestyle and/or dietary restrictions outlined in protocol.

• High-risk behavior for HIV infection which includes, but is not limited to, one of the following risk factors within six months before entering the study (Day 1 of the oral lead-in): Unprotected vaginal or anal sex with a known HIV infected person or a casual partner, engaged in sex work for money or drugs, acquired a sexually transmitted disease, high risk partner currently or in the previous six months or intravenous drug use.

• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.

• For subjects participating in magnetic resonance imaging (MRI) imaging: Contraindication for MRI scanning (as assessed by local MRI safety questionnaire), which includes but is not limited to: a) Intracranial aneurysm clips (except Sugita) or other non-MRI compatible metallic objects; b) Intra- orbital metal fragments that have not been removed by a medical professional; c) Pacemakers or other implanted cardiac rhythm management devices and non-MRI compatible heart valves, d) Inner ear implants, e) History of claustrophobia

• Positive hepatitis B surface antigen or positive hepatitis B core antibody with negative hepatitis B surface antibody test result at screening or within 3 months prior to first dose of study treatment.

• Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment

• A positive pre-study drug/alcohol screen. A positive drug screen is permitted if due to a prescribed medication, provided that medication is not on the list of prohibited medications and approved by the investigator and medical monitor.

• A positive test for HIV antibody.

• A positive pre-study screen for sexually transmitted diseases including Neisseria gonorrhea or Chlamydia trachomatis, Trichomonas, syphilis, or an active Herpes simplex virus (HSV) genital lesion.

• Presence of a tattoo or other dermatological condition overlying the buttocks which in the opinion of the investigator may interfere with the interpretation of injection site reactions.

• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.

• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.

• Unwillingness or inability to follow the procedures outlined in the protocol.

• Subject is mentally or legally incapacitated.

Additional Criteria for Female Subjects Only:

• Any current medical conditions that in the opinion of the investigator may compromise the conduct or analysis of the genital tract sampling (e.g., active genital tract infection or lesions).

• Inability to abstain from the use of intravaginal products (e.g. tampons, spermicides, lubricants, vaginal hygiene products, diaphragms) for 72 hours prior to the genital tract sample collection visits and for up to 72 hours after.

• Inability to abstain from any sexual activity (e.g., vaginal intercourse, masturbation, and penetration of the vagina by penises, fingers, tampons, sex toys) for 72 hours prior to the genital tract sample collection visits and for up to 72 hours after.

Additional Criteria for Male Subjects and Female Subjects who consent to rectal PK sampling:

• Any current medical conditions that in the opinion of the investigator may compromise the conduct or analysis of the rectal compartment sampling (e.g., active rectal compartment infection, lesions or disease).

• Inability to abstain from the use of intrarectal products (e.g., suppositories, lubricants) for 72 hours prior to the rectal compartment sample collection visits and for up to 72 hours after.

• Inability to abstain from any receptive anal sexual activity (e.g., anal receptive intercourse and penetration of the rectum by fingers, sex toys or other) for 72 hours prior to the rectal compartment sample collection visit and for up to 72 hours after.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	GSK Investigational Site	Baltimore	Maryland	United States	21287-5554
2	GSK Investigational Site	Pittsburgh	Pennsylvania	United States	15213

Sponsors and Collaborators

• ViiV Healthcare

Investigators

• Study Director: GSK Clinical Trials, ViiV Healthcare

Study Documents (Full-Text)

• Statistical Analysis Plan - Aug 14, 2019
• Study Protocol - Aug 14, 2017

More Information

Publications

None provided.

• Responsible Party: ViiV Healthcare
• ClinicalTrials.gov Identifier: NCT02478463
• Other Study ID Numbers: 201767
• First Posted: Jun 23, 2015
• Last Update Posted: Jun 22, 2020
• Last Verified: Jun 1, 2020

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by ViiV Healthcare: Cabotegravir; Pharmacokinetic; Healthy Adult Volunteers; GSK1265744
• Additional relevant MeSH terms: Infections; Communicable Diseases; HIV Infections; Acquired Immunodeficiency Syndrome; Cabotegravir

Study Results

Participant Flow

Recruitment Details	This was a Phase 1, open label study in healthy participants to assess the pharmacokinetics of cabotegravir (CAB) long-acting (LA) in the blood plasma and anatomical tissues and secretions associated with sexual human immunodeficiency virus (HIV)-1 transmission. The study was conducted across two centers in the United States.
Pre-assignment Detail	A total of 29 participants were screened, of which 10 failed screening. A total of 19 participants were enrolled in the study and received study treatment.

Arm/Group Title	Cabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg
Arm/Group Description	Participants received once daily oral dose of 30 milligram (mg) cabotegravir for 28 days during the oral lead-in phase in Period 1 followed by a single intramuscular (IM) dose of 600 mg cabotegravir in Period 2. There was a washout period of up to 42 days between the two treatment periods.
Period Title: Treatment Period 1 (Up to Day 29)
STARTED	19
COMPLETED	18
NOT COMPLETED	1
Period Title: Treatment Period 1 (Up to Day 29)
STARTED	18
COMPLETED	17
NOT COMPLETED	1
Period Title: Treatment Period 1 (Up to Day 29)
STARTED	17
COMPLETED	16
NOT COMPLETED	1

Baseline Characteristics

Arm/Group Title	Cabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg
Arm/Group Description	Participants received once daily oral dose of 30 milligram (mg) cabotegravir for 28 days during the oral lead-in phase in Period 1 followed by a single intramuscular (IM) dose of 600 mg cabotegravir in Period 2. There was a washout period of up to 42 days between the two treatment periods.
Overall Participants	19
Age (Years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Years]	33.3 (9.12)
Sex: Female, Male (Count of Participants)
Female	10 52.6%
Male	9 47.4%
Race/Ethnicity, Customized (Count of Participants)
Asian - South East Asian Heritage	1 5.3%
Black or African American	6 31.6%
White - White/Caucasian/European Heritage	12 63.2%

Outcome Measures

1. Primary Outcome

Title	Cabotegravir Concentration in Blood Plasma Following IM Administration
Description	Blood samples were collected to measure cabotegravir concentration in blood plasma following a single 600 mg IM dose at indicated time-points. Evaluable Pharmacokinetic (PK) Plasma Parameter Summary Population comprised of all participants who underwent plasma PK sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and had evaluable PK parameters estimated and no major protocol deviation.
Time Frame	Day 1: Pre-dose and 4 hours; one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36 and 52 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable PK Plasma Parameter Summary Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	15
Day 1: Pre-dose, n=15	0.0000 (NA)
Day 1: 4 hours, n=15	0.2864 (0.10463)
Day 3, n=15	3.2748 (1.74419)
Day 5, n=15	5.1071 (3.09180)
Day 8, n=15	5.0433 (2.92704)
Week 4, n=15	2.5583 (1.00963)
Week 8, n=15	0.9683 (0.73601)
Week 12, n=15	0.3925 (0.40471)
Week 24, n=15	0.0550 (NA)
Week 36, n=15	0.0213 (NA)
Week 52, n=14	0.0089 (NA)

2. Primary Outcome

Title	Cabotegravir Concentration in Vaginal Tissue Following IM Administration (Female Participants)
Description	Vaginal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points. Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM) comprised of all participants who underwent sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and have both evaluable PK and evaluable tissues-fluid parameters estimated in vaginal tissue/cervical tissue/cervicovaginal fluid/rectal tissue/rectal fluid.
Time Frame	One sample on Day 3 and Week 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Day 3	0.5286 (0.48215)
Week 8	0.1809 (0.14606)

3. Primary Outcome

Title	Cabotegravir Concentration in Cervical Tissue Following IM Administration (Female Participants)
Description	Cervical tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Day 3	0.8016 (0.70126)
Day 8	0.9261 (0.85513)
Week 4	0.4409 (0.29216)
Week 8	0.1570 (0.14909)
Week 12	0.0460 (NA)

4. Primary Outcome

Title	Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)
Description	Cervicovaginal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Day 3	0.6604 (0.91588)
Day 8	0.6175 (0.59792)
Week 4	0.3209 (0.37093)
Week 8	0.0905 (0.14821)
Week 12	0.0901 (0.18306)

5. Primary Outcome

Title	Cabotegravir Concentration in Rectal Tissue Following IM Administration
Description	Rectal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	13
Day 3	0.2824 (0.17814)
Day 8	0.5146 (0.26514)
Week 4	0.2620 (0.10476)
Week 8	0.1037 (0.10050)
Week 12	0.0348 (NA)

6. Primary Outcome

Title	Cabotegravir Concentration in Rectal Fluid Following IM Administration
Description	Rectal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Day 3	1.3868 (1.88097)
Day 8	3.2046 (2.68417)
Week 4	5.2674 (7.99949)
Week 8	0.3233 (0.22764)
Week 12	0.7901 (1.75430)

7. Secondary Outcome

Title	Ratio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)
Description	Vaginal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in blood plasma is presented.
Time Frame	One sample on Day 3 and Week 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Day 3	0.128 (43.38)
Week 8	0.199 (32.66)

8. Secondary Outcome

Title	Ratio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)
Description	Cervical tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in blood plasma is presented.
Time Frame	One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Day 3	0.203 (36.14)
Day 8	0.174 (44.85)
Week 4	0.139 (99.93)
Week 8	0.139 (59.16)
Week 12	0.101 (45.10)

9. Secondary Outcome

Title	Ratio of Cabotegravir Concentration in Cervicovaginal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)
Description	Cervicovaginal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervicovaginal fluid to cabotegravir concentration in blood plasma is presented.
Time Frame	One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Day 3	0.116 (174.76)
Day 8	0.124 (73.53)
Week 4	0.073 (277.59)
Week 8	0.057 (101.03)
Week 12	0.082 (112.91)

10. Secondary Outcome

Title	Ratio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)
Description	Cervical tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in cervicovaginal fluid is presented.
Time Frame	One sample on Day 3, 8, Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Day 3	1.738 (118.75)
Day 8	1.405 (81.10)
Week 4	1.883 (172.44)
Week 8	2.785 (110.92)
Week 12	1.195 (105.01)

11. Secondary Outcome

Title	Ratio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)
Description	Vaginal tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in cervicovaginal fluid is presented.
Time Frame	One sample on Day 3 and Week 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Day 3	1.095 (233.20)
Week 8	3.613 (115.25)

12. Secondary Outcome

Title	Ratio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration
Description	Rectal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in blood plasma is presented.
Time Frame	One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	13
Day 3	0.078 (43.13)
Day 8	0.105 (22.92)
Week 4	0.104 (18.79)
Week 8	0.096 (27.81)
Week 12	0.091 (38.62)

13. Secondary Outcome

Title	Ratio of Cabotegravir Concentration in Rectal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration
Description	Rectal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal fluid to cabotegravir concentration in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Day 3	0.286 (157.60)
Day 8	0.581 (140.37)
Week 4	0.460 (923.37)
Week 8	0.302 (140.54)
Week 12	0.514 (185.97)

14. Secondary Outcome

Title	Ratio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Rectal Fluid Following IM Administration
Description	Rectal tissue and rectal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in rectal fluid is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Day 3, n=11	0.271 (150.25)
Day 8, n=12	0.185 (140.92)
Week 4, n=12	0.230 (1082.13)
Week 8, n=12	0.366 (133.20)
Week 12, n=12	0.093 (294.16)

15. Secondary Outcome

Title	Maximum Observed Concentration (Cmax) of Cabotegravir in Blood Plasma Following IM Administration
Description	Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable PK Plasma Parameter Summary Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	15
Geometric Mean (Geometric Coefficient of Variation) [Micrograms per milliliter]	5.04 (62.0)

16. Secondary Outcome

Title	Cmax of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Description	Cervical tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Micrograms per milliliter]	0.81 (105.0)

17. Secondary Outcome

Title	Cmax of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Description	Cervicovaginal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Micrograms per milliliter]	0.55 (118.3)

18. Secondary Outcome

Title	Cmax of Cabotegravir in Rectal Tissue Following IM Administration
Description	Rectal tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	13
Geometric Mean (Geometric Coefficient of Variation) [Micrograms per milliliter]	0.50 (47.0)

19. Secondary Outcome

Title	Cmax of Cabotegravir in Rectal Fluid Following IM Administration
Description	Rectal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Geometric Mean (Geometric Coefficient of Variation) [Micrograms per milliliter]	3.27 (171.9)

20. Secondary Outcome

Title	Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC[0-last]) for Cabotegravir in Blood Plasma Following IM Administration
Description	Blood samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	Day 1: Pre-dose, 4 hours, One sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable PK Plasma Parameter Summary Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	15
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	3992.25 (24.5)

21. Secondary Outcome

Title	AUC(0-last) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Description	Cervical tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	522.73 (77.0)

22. Secondary Outcome

Title	AUC(0-last) of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Description	Cervicovaginal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	324.33 (121.4)

23. Secondary Outcome

Title	AUC(0-last) for Cabotegravir in Rectal Tissue Following IM Administration
Description	Rectal tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	13
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	347.73 (35.5)

24. Secondary Outcome

Title	AUC(0-last) for Cabotegravir in Rectal Fluid Following IM Administration
Description	Rectal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	1841.23 (193.8)

25. Secondary Outcome

Title	Area Under the Concentration Time Curve From Time Zero to Infinity (AUC[0-inf]) for Cabotegravir in Blood Plasma Following IM Administration
Description	Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable PK Plasma Parameter Summary Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	14
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	4172.17 (23.9)

26. Secondary Outcome

Title	AUC(0-inf) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Description	Cervical tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	1
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	695.72 (NA)

27. Secondary Outcome

Title	AUC(0-inf) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Description	Cervicovaginal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	4
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	399.07 (99.9)

28. Secondary Outcome

Title	AUC(0-inf) for Cabotegravir in Rectal Tissue Following IM Administration
Description	Rectal tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	3
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	291.98 (34.6)

29. Secondary Outcome

Title	AUC(0-inf) for Cabotegravir in Rectal Fluid Following IM Administration
Description	Rectal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	2
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	850.05 (42.7)

30. Secondary Outcome

Title	Area Under the Concentration Time Curve From Time Zero to Week (WK) 4 (AUC[0-WK4]) for Cabotegravir in Blood Plasma Following IM Administration
Description	Blood samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8 and Week 4 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable PK Plasma Parameter Summary Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	15
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	2141.91 (59.2)

31. Secondary Outcome

Title	AUC(0-WK4) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Description	Cervical tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8 and Week 4 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	277.48 (103.6)

32. Secondary Outcome

Title	AUC(0-WK4) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Description	Cervicovaginal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8 and Week 4 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	203.32 (125.5)

33. Secondary Outcome

Title	AUC(0-WK4) for Cabotegravir in Rectal Tissue Following IM Administration
Description	Rectal tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8 and Week 4 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	206.28 (57.2)

34. Secondary Outcome

Title	AUC(0-WK4) for Cabotegravir in Rectal Fluid Following IM Administration
Description	Rectal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8 and Week 4 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	1170.49 (192.1)

35. Secondary Outcome

Title	Area Under the Concentration Time Curve From Time Zero to Week 8 (AUC[0-WK8]) for Cabotegravir in Blood Plasma Following IM Administration
Description	Blood samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4 and 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable PK Plasma Parameter Summary Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	15
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	3213.62 (40.1)

36. Secondary Outcome

Title	AUC(0-WK8) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Description	Cervical tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4 and 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	4
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	364.74 (85.2)

37. Secondary Outcome

Title	AUC(0-WK8) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Description	Cervicovaginal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4 and 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	281.60 (124.8)

38. Secondary Outcome

Title	AUC(0-WK8) for Cabotegravir in Rectal Tissue Following IM Administration
Description	Rectal tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4 and 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	287.35 (38.7)

39. Secondary Outcome

Title	AUC(0-WK8) for Cabotegravir in Rectal Fluid Following IM Administration
Description	Rectal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4 and 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	1575.54 (202.9)

40. Secondary Outcome

Title	Area Under the Concentration Time Curve From Time Zero to Week 12 (AUC[0-WK12]) for Cabotegravir in Blood Plasma Following IM Administration
Description	Blood samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable PK Plasma Parameter Summary Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	14
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	3639.01 (35.6)

41. Secondary Outcome

Title	AUC(0-WK12) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Description	Cervical tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	3
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	349.98 (78.9)

42. Secondary Outcome

Title	AUC(0-WK12) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Description	Cervicovaginal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	4
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	380.92 (107.8)

43. Secondary Outcome

Title	AUC(0-WK12) for Cabotegravir in Rectal Tissue Following IM Administration
Description	Rectal tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	4
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	323.91 (54.8)

44. Secondary Outcome

Title	AUC(0-WK12) for Cabotegravir in Rectal Fluid Following IM Administration
Description	Rectal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Hours*microgram per milliliter]	1345.13 (137.7)

45. Secondary Outcome

Title	Apparent Terminal Phase Half-life (t1/2) of Cabotegravir in Blood Plasma Following IM Administration
Description	Blood samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable PK Plasma Parameter Summary Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	14
Geometric Mean (Geometric Coefficient of Variation) [Hours]	459.53 (81.4)

46. Secondary Outcome

Title	t1/2 of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Description	Cervical tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	1
Geometric Mean (Geometric Coefficient of Variation) [Hours]	363.41 (NA)

47. Secondary Outcome

Title	t1/2 of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Description	Cervicovaginal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	4
Geometric Mean (Geometric Coefficient of Variation) [Hours]	355.83 (79.4)

48. Secondary Outcome

Title	t1/2 of Cabotegravir in Rectal Tissue Following IM Administration
Description	Rectal tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	3
Geometric Mean (Geometric Coefficient of Variation) [Hours]	567.48 (23.3)

49. Secondary Outcome

Title	t1/2 of Cabotegravir in Rectal Fluid Following IM Administration
Description	Rectal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	2
Geometric Mean (Geometric Coefficient of Variation) [Hours]	306.58 (3.5)

50. Secondary Outcome

Title	Ratio of AUC(0-last) in Cervical Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Description	Cervical tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervical tissue to AUC(0-last) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.1215 (64.86)

51. Secondary Outcome

Title	Ratio of AUC(0-last) in Rectal Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration
Description	Rectal tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal tissue to AUC(0-last) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	13
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.0849 (21.13)

52. Secondary Outcome

Title	Ratio of AUC(0-inf) in Cervical Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Description	Cervical tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervical tissue to AUC(0-inf) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	1
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.1943 (NA)

53. Secondary Outcome

Title	Ratio of AUC(0-inf) in Rectal Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration
Description	Rectal tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal tissue to AUC(0-inf) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	3
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.0766 (42.26)

54. Secondary Outcome

Title	Ratio of AUC(0-Wk4) in Cervical Tissue to AUC(0-Wk4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Description	Cervical tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervical tissue to AUC(0-WK4) in blood plasma is presented.
Time Frame	One sample on Days 3, 8 and Week 4 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	6
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.1553 (50.33)

55. Secondary Outcome

Title	Ratio of AUC(0-Wk 4) in Rectal Tissue to AUC(0-Wk 4) in Blood Plasma for Cabotegravir Following IM Administration
Description	Rectal tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal tissue to AUC(0-WK4) in blood plasma is presented.
Time Frame	One sample on Days 3, 8 and Week 4 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.1000 (19.30)

56. Secondary Outcome

Title	Ratio of AUC(0-WK8) in Cervical Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Description	Cervical tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervical tissue to AUC(0-WK8) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4 and 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	4
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.1492 (52.30)

57. Secondary Outcome

Title	Ratio of AUC(0-WK8) in Rectal Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration
Description	Rectal tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal tissue to AUC(0-WK8) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4 and 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.1062 (17.46)

58. Secondary Outcome

Title	Ratio of AUC(0-WK12) in Cervical Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Description	Cervical tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervical tissue to AUC(0-WK12) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	3
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.1230 (48.22)

59. Secondary Outcome

Title	Ratio of AUC(0-WK12) in Rectal Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration
Description	Rectal tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal tissue to AUC(0-WK12) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	4
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.1089 (13.50)

60. Secondary Outcome

Title	Ratio of AUC(0-last) in Cervicovaginal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration-female Participants
Description	Cervicovaginal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervicovaginal fluid to AUC(0-last) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.0754 (99.37)

61. Secondary Outcome

Title	Ratio of AUC(0-last) in Rectal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration
Description	Rectal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal fluid to AUC(0-last) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.4445 (204.26)

62. Secondary Outcome

Title	Ratio of AUC(0-inf) in Cervicovaginal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Description	Cervicovaginal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervicovaginal fluid to AUC(0-inf) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	4
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.0857 (99.10)

63. Secondary Outcome

Title	Ratio of AUC(0-inf) in Rectal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration
Description	Rectal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal fluid to AUC(0-inf) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	2
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.1949 (80.06)

64. Secondary Outcome

Title	Ratio of AUC(0-WK4) in Cervicovaginal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Description	Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervicovaginal fluid to AUC(0-WK4) in blood plasma is presented.
Time Frame	One sample on Days 3, 8 and Week 4 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.1032 (119.71)

65. Secondary Outcome

Title	Ratio of AUC(0-WK4) in Rectal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration
Description	Rectal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal fluid to AUC(0-WK4) in blood plasma is presented.
Time Frame	One sample on Days 3, 8 and Week 4 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.5452 (223.58)

66. Secondary Outcome

Title	Ratio of AUC(0-WK8) in Cervicovaginal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Description	Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervicovaginal fluid to AUC(0-WK8) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4 and 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.0925 (124.99)

67. Secondary Outcome

Title	Ratio of AUC(0-WK8) in Rectal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration
Description	Rectal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal fluid to AUC(0-WK8) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4 and 8 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	12
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.4845 (212.20)

68. Secondary Outcome

Title	Ratio of AUC(0-WK12) in Cervicovaginal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Description	Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervicovaginal fluid to AUC(0-WK12) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	4
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.0867 (99.56)

69. Secondary Outcome

Title	Ratio of AUC(0-WK12) in Rectal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration
Description	Rectal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal fluid to AUC(0-WK12) in blood plasma is presented.
Time Frame	One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	7
Geometric Mean (Geometric Coefficient of Variation) [Ratio]	0.3863 (154.56)

70. Secondary Outcome

Title	Cabotegravir Concentration in Vaginal Tissue Following Oral Administration (Female Participants)
Description	Vaginal tissue samples were collected to measure cabotegravir concentration in vaginal tissue following oral 30 mg dose at indicated time-points.
Time Frame	24 hours post-dose on Day 28

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	7
Mean (Standard Deviation) [Micrograms per milliliter]	0.7477 (0.50171)

71. Secondary Outcome

Title	Cabotegravir Concentration in Cervical Tissue Following Oral Administration (Female Participants)
Description	Cervical tissue samples were collected to measure cabotegravir concentration in cervical tissue following oral 30 mg dose at indicated time-points.
Time Frame	24 hours post-dose on Day 28

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	7
Mean (Standard Deviation) [Micrograms per milliliter]	1.1009 (0.53987)

72. Secondary Outcome

Title	Cabotegravir Concentration in Cervicovaginal Fluid Following Oral Administration (Female Participants)
Description	Cervicovaginal fluid samples were collected to measure cabotegravir concentration in cervicovaginal fluid following oral 30 mg dose at indicated time-points.
Time Frame	24 hours post-dose on Day 28

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	7
Mean (Standard Deviation) [Micrograms per milliliter]	0.8959 (0.95662)

73. Secondary Outcome

Title	Cabotegravir Concentration in Rectal Tissue Following Oral Administration
Description	Rectal tissue samples were collected to measure cabotegravir concentration in rectal tissue following oral 30 mg dose at indicated time-points.
Time Frame	24 hours post-dose on Day 28

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	13
Mean (Standard Deviation) [Micrograms per milliliter]	0.6104 (0.24854)

74. Secondary Outcome

Title	Cabotegravir Concentration in Rectal Fluid Following Oral Administration
Description	Rectal fluid samples were collected to measure cabotegravir concentration in rectal fluid following oral 30 mg dose at indicated time-points.
Time Frame	24 hours post-dose on Day 28

Outcome Measure Data

Analysis Population Description

Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM). Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	12
Mean (Standard Deviation) [Micrograms per milliliter]	5.5457 (6.41639)

75. Secondary Outcome

Title	Cabotegravir Concentration in Blood Plasma Following Oral Administration
Description	Blood samples were collected to measure cabotegravir concentration in blood plasma following oral 30 mg dose at indicated time-points.
Time Frame	24 hours post-dose on Day 28

Outcome Measure Data

Analysis Population Description

Evaluable PK Plasma Parameter Summary Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	15
Mean (Standard Deviation) [Micrograms per milliliter]	5.7313 (2.08899)

76. Secondary Outcome

Title	Number of Participants With Any Non-serious Adverse Event (Non-SAE) and Serious Adverse Events (SAE) Following Oral Administration of Cabotegravir
Description	An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.
Time Frame	Up to Day 29

Outcome Measure Data

Analysis Population Description

Safety Population comprised of all participants who received at least one dose of study drug.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	19
Any Non-SAE	10 52.6%
Any SAE	0 0%

77. Secondary Outcome

Title	Number of Participants With Any Non-SAE and SAE Following IM Administration of Cabotegravir
Description	An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.
Time Frame	Up to Week 52

Outcome Measure Data

Analysis Population Description

Safety Population

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Any Non-SAE	17 89.5%
Any SAE	2 10.5%

78. Secondary Outcome

Title	Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Amino Transferase (AST) at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
ALT, Day 14	1.7 (8.98)
ALT, Day 29	3.5 (10.12)
ALP, Day 14	-0.2 (6.44)
ALP, Day 29	-0.4 (3.24)
AST, Day 14	-0.3 (3.60)
AST, Day 29	1.1 (6.14)

79. Secondary Outcome

Title	Change From Baseline in ALT, ALP and AST at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
ALT, Week 4, n=17	-0.2 (4.05)
ALT, Week 8, n=16	-0.8 (5.33)
ALT, Week 12, n=16	-1.4 (3.81)
ALP, Week 4, n=15	2.1 (6.39)
ALP, Week 8, n=16	0.6 (8.43)
ALP, Week 12, n=16	1.3 (6.57)
AST, Week 4, n=17	0.1 (2.87)
AST, Week 8, n=16	0.1 (3.76)
AST, Week 12, n=16	-0.1 (3.50)

80. Secondary Outcome

Title	Change From Baseline in Creatine Kinase at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Day 14	-19.9 (27.23)
Day 29	-8.9 (46.56)

81. Secondary Outcome

Title	Change From Baseline in Creatine Kinase at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	16
Week 8	19.6 (67.42)
Week 12	22.2 (92.09)

82. Secondary Outcome

Title	Change From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Creatinine, Day 14, n=18	0.491 (5.6500)
Creatinine, Day 29, n=18	-0.491 (7.0929)
Direct bilirubin, Day 14, n=11	-0.311 (0.6917)
Direct bilirubin, Day 29, n=12	0.428 (0.7734)
Total bilirubin, Day 14, n=16	-1.282 (1.9245)
Total bilirubin, Day 29, n=16	0.000 (2.7217)

83. Secondary Outcome

Title	Change From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Creatinine, Week 4, n=17	-3.640 (8.3037)
Creatinine, Week 8, n=16	-5.525 (5.4732)
Creatinine, Week 12, n=16	-3.315 (8.4637)
Direct bilirubin, Week 4, n=10	-0.171 (0.5407)
Direct bilirubin, Week 8, n=10	0.171 (1.2617)
Direct bilirubin, Week 12, n=9	0.190 (1.3368)
Total bilirubin, Week 4, n=16	0.641 (3.1142)
Total bilirubin, Week 8, n=15	0.114 (4.2118)
Total bilirubin, Week 12, n=14	1.099 (4.5789)

84. Secondary Outcome

Title	Change From Baseline in Albumin and Total Protein at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Albumin, Day 14	-0.6 (2.85)
Albumin, Day 29	-0.3 (1.53)
Total protein, Day 14	-1.7 (3.48)
Total protein, Day 29	-1.4 (2.23)

85. Secondary Outcome

Title	Change From Baseline in Albumin and Total Protein at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Albumin, Week 4, n=17	0.3 (2.66)
Albumin, Week 8, n=16	0.3 (2.41)
Albumin, Week 12, n=16	0.6 (2.42)
Total protein, Week 4, n=17	0.2 (3.23)
Total protein, Week 8, n=15	-0.1 (3.53)
Total protein, Week 12, n=16	0.5 (4.31)

86. Secondary Outcome

Title	Change From Baseline in Calcium, Glucose, Potassium, Sodium and Urea Enzymatic Colorimetry at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and urea enzymatic colorimetry (UEC) following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Calcium, Day 14	-0.027722 (0.0905221)
Calcium, Day 29	-0.033267 (0.0774940)
Glucose, Day 14	0.391654 (0.6929202)
Glucose, Day 29	0.672288 (1.0302415)
Potassium, Day 14	-0.05 (0.296)
Potassium, Day 29	-0.04 (0.241)
Sodium, Day 14	-0.9 (1.53)
Sodium, Day 29	-0.3 (2.43)
UEC, Day 14	-0.2975 (0.97384)
UEC, Day 29	-0.2578 (1.14741)

87. Secondary Outcome

Title	Change From Baseline in Calcium, Glucose, Potassium, Sodium and UEC at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and UEC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Calcium, Week 4, n=17	-0.002935 (0.0763335)
Calcium, Week 8, n=15	-0.003327 (0.0610177)
Calcium, Week 12, n=16	-0.001559 (0.0666177)
Glucose, Week 4, n=17	-0.111020 (0.6467570)
Glucose, Week 8, n=16	-0.003469 (0.8073398)
Glucose, Week 12, n=16	-0.149183 (0.6402427)
Potassium, Week 4, n=17	-0.08 (0.260)
Potassium, Week 8, n=16	-0.07 (0.236)
Potassium, Week 12, n=16	0.01 (0.379)
Sodium, Week 4, n=17	-0.4 (2.06)
Sodium, Week 8, n=16	0.1 (1.77)
Sodium, Week 12, n=16	-0.6 (1.79)
UEC, Week 4, n=17	-0.5250 (1.01068)
UEC, Week 8, n=16	-0.6694 (1.20801)
UEC, Week 12, n=16	-0.3570 (1.18762)

88. Secondary Outcome

Title	Change From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	2
Basophils, Day 14, n=1	-0.30 (NA)
Basophils, Day 29, n=2	-0.05 (0.212)
Eosinophils, Day 14, n=1	0.000 (NA)
Eosinophils, Day 29, n=2	0.100 (0.1414)
Lymphocytes, Day 14, n=1	0.500 (NA)
Lymphocytes, Day 29, n=2	0.400 (0.1414)
Monocytes, Day 14, n=1	0.000 (NA)
Monocytes, Day 29, n=2	-0.100 (0.0000)

89. Secondary Outcome

Title	Change From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4 and 8

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	3
Basophils, Week 4, n=3	0.03 (0.058)
Basophils, Week 8, n=1	0.00 (NA)
Eosinophils, Week 4, n=3	0.000 (0.0000)
Eosinophils, Week 8, n=1	0.000 (NA)
Lymphocytes, Week 4, n=3	0.073 (0.3607)
Lymphocytes, Week 8, n=1	-0.300 (NA)
Monocytes, Week 4, n=3	-0.040 (0.2425)
Monocytes, Week 8, n=1	0.000 (NA)

90. Secondary Outcome

Title	Change From Baseline in Total Neutrophil Count at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of hematology parameter; total neutrophils count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	11
Day 14, n=9	-0.353 (0.6194)
Day 29, n=11	-0.565 (1.1071)

91. Secondary Outcome

Title	Change From Baseline in Total Neutrophil Count at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of hematology parameters; total neutrophil count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	11
Week 4, n=11	0.539 (0.9379)
Week 8, n=8	0.010 (0.8206)
Week 12, n=7	-0.076 (0.7115)

92. Secondary Outcome

Title	Change From Baseline in Platelet Count and White Blood Cell (WBC) Count at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Platelets, Day 1 (post-dose), n=1	39.0 (NA)
Platelets, Day 14, n=17	-6.6 (30.83)
Platelets, Day 29, n=18	8.7 (29.14)
WBCs, Day 1, n=1	2.100 (NA)
WBCs, Day 14, n=17	-0.056 (0.8815)
WBCs, Day 29, n=18	-0.263 (1.1894)

93. Secondary Outcome

Title	Change From Baseline in Platelet Count and WBC Count at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Platelets, Week 4, n=17	11.7 (21.00)
Platelets, Week 8, n=16	12.0 (25.72)
Platelets, Week 12, n=16	7.3 (18.34)
WBCs, Week 4, n=17	-0.053 (1.1486)
WBCs, Week 8, n=16	-0.085 (0.7777)
WBCs, Week 12, n=16	-0.159 (0.9395)

94. Secondary Outcome

Title	Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Hemoglobin, Day 1 (post-dose), n=1	-6.0 (NA)
Hemoglobin, Day 14, n=17	-5.1 (7.60)
Hemoglobin, Day 29, n=18	-3.6 (6.93)
MCHC, Day 1 (post-dose), n=1	-8.0 (NA)
MCHC, Day 14, n=17	-1.2 (6.93)
MCHC, Day 29, n=18	1.3 (7.81)

95. Secondary Outcome

Title	Change From Baseline in Hemoglobin and MCHC at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Hemoglobin, Week 4, n=17	-0.8 (5.25)
Hemoglobin, Week 8, n=16	0.8 (6.56)
Hemoglobin, Week 12, n=16	1.4 (7.31)
MCHC, Week 4, n=17	0.9 (7.39)
MCHC, Week 8, n=16	-0.8 (6.33)
MCHC, Week 12, n=16	1.8 (6.84)

96. Secondary Outcome

Title	Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Day 1 (post-dose), n=1	-0.90 (NA)
Day 14, n=17	-0.22 (0.629)
Day 29, n=18	-0.01 (0.567)

97. Secondary Outcome

Title	Change From Baseline in MCH at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Week 4, n=17	-0.15 (0.292)
Week 8, n=16	-0.39 (0.584)
Week 12, n=16	-0.36 (0.778)

98. Secondary Outcome

Title	Change From Baseline in Mean Corpuscle Volume (MCV) at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Day 1 (post-dose), n=1	-0.20 (NA)
Day 14, n=17	-0.40 (1.052)
Day 29, n=18	-0.34 (1.303)

99. Secondary Outcome

Title	Change From Baseline in MCV at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Week 4, n=17	-0.67 (1.771)
Week 8, n=16	-1.03 (1.799)
Week 12, n=16	-1.63 (1.861)

100. Secondary Outcome

Title	Change From Baseline in Hematocrit at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Day 1 (post-dose), n=1	-0.0060 (NA)
Day 14, n=17	-0.0135 (0.02456)
Day 29, n=18	-0.0122 (0.02084)

101. Secondary Outcome

Title	Change From Baseline in Hematocrit at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Week 4, n=17	-0.0034 (0.01703)
Week 8, n=16	0.0030 (0.02145)
Week 12, n=16	0.0025 (0.02196)

102. Secondary Outcome

Title	Change From Baseline in Red Blood Cell (RBC) Count at Indicated Time Points (Oral Dose)
Description	Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Day 1 (post-dose), n=1	-0.050 (NA)
Day 14, n=17	-0.126 (0.2813)
Day 29, n=18	-0.114 (0.2360)

103. Secondary Outcome

Title	Change From Baseline in RBC Count at Indicated Time Points (IM Dose)
Description	Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Week 4, n=17	-0.004 (0.1718)
Week 8, n=16	0.087 (0.2129)
Week 12, n=16	0.117 (0.2266)

104. Secondary Outcome

Title	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time Points (Oral Dose)
Description	SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
SBP, Day 14	-1.3 (8.55)
SBP, Day 29	-1.0 (8.64)
DBP, Day 14	-0.9 (7.57)
DBP, Day 29	0.5 (5.96)

105. Secondary Outcome

Title	Change From Baseline in SBP and DBP at Indicated Time Points (IM Dose)
Description	SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
SBP, Day 3, n=17	0.1 (10.15)
SBP, Day 5, n=17	-1.5 (10.44)
SBP, Day 8, n=17	3.2 (13.18)
SBP, Week 4, n=17	1.8 (12.11)
SBP, Week 8, n=16	0.9 (9.23)
SBP, Week 12, n=16	-1.1 (11.69)
SBP, Week 24, n=16	2.0 (12.88)
SBP, Week 36, n=16	1.7 (11.44)
SBP, Week 52, n=15	0.7 (13.08)
DBP, Day 3, n=17	0.5 (4.11)
DBP, Day 5, n=17	-0.7 (4.69)
DBP, Day 8, n=17	0.6 (5.36)
DBP, Week 4, n=17	-0.4 (5.20)
DBP, Week 8, n=16	3.3 (5.65)
DBP, Week 12, n=16	0.2 (4.46)
DBP, Week 24, n=16	1.0 (4.98)
DBP, Week 36, n=16	2.3 (5.47)
DBP, Week 52, n=15	0.1 (9.23)

106. Secondary Outcome

Title	Change From Baseline in Pulse Rate at Indicated Time Points (Oral Dose)
Description	Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Day 14	-1.0 (5.72)
Day 29	2.4 (8.23)

107. Secondary Outcome

Title	Change From Baseline in Pulse Rate at Indicated Time Points (IM Dose)
Description	Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Day 3, n=17	-0.9 (10.51)
Day 5, n=17	6.2 (7.66)
Day 8, n=17	1.6 (9.06)
Week 4, n=17	-0.6 (7.40)
Week 8, n=16	-0.9 (7.85)
Week 12, n=16	1.3 (11.80)
Week 24, n=16	1.1 (6.87)
Week 36, n=16	2.6 (11.07)
Week 52, n=15	1.9 (10.59)

108. Secondary Outcome

Title	Change From Baseline in Body Temperature at Indicated Time Points (Oral Dose)
Description	Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 14 and 29

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	18
Day 14	-0.2 (0.54)
Day 29	-0.1 (0.46)

109. Secondary Outcome

Title	Change From Baseline in Body Temperature at Indicated Time Points (IM Dose)
Description	Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time Frame	Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52

Outcome Measure Data

Analysis Population Description

Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	17
Day 3, n=17	-0.0 (0.36)
Day 5, n=17	0.2 (0.52)
Day 8, n=17	0.0 (0.37)
Week 4, n=17	-0.1 (0.31)
Week 8, n=16	-0.0 (0.47)
Week 12, n=16	0.2 (0.37)
Week 24, n=16	-0.0 (0.39)
Week 36, n=16	-0.1 (0.58)
Week 52, n=15	0.1 (0.61)

110. Secondary Outcome

Title	Number of Participants With Abnormal Urinalysis Parameters Following Oral Administration of Cabotegravir
Description	Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.
Time Frame	Up to Day 29

Outcome Measure Data

Analysis Population Description

Safety Population. This analysis was not planned and data was not collected and not captured in the database.

Arm/Group Title	Cabotegravir Oral 30 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.
Measure Participants	0

111. Secondary Outcome

Title	Number of Participants With Abnormal Urinalysis Parameters Following IM Administration of Cabotegravir
Description	Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.
Time Frame	Up to Week 52

Outcome Measure Data

Analysis Population Description

Safety Population. This analysis was not planned and data was not collected and not captured in the database.

Arm/Group Title	Cabotegravir IM 600 mg
Arm/Group Description	All participants received single IM dose of 600 mg cabotegravir in Period 2.
Measure Participants	0

Adverse Events

Time Frame	Non-SAEs and SAEs were collected from the start of study treatment up to Day 29 for Period 1 (Oral dose) and up to Week 52 for Period 2 (IM dose)
Adverse Event Reporting Description	Non-SAE and SAEs were reported for Safety Population.
Arm/Group Title	Cabotegravir Oral 30 mg		Cabotegravir IM 600 mg
Arm/Group Description	All participants received oral 30 mg dose of CAB once per day for 28 days in Period 1.		All participants received single IM dose of 600 mg cabotegravir in Period 2.
All Cause Mortality
	Cabotegravir Oral 30 mg		Cabotegravir IM 600 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/19 (0%)		0/17 (0%)
Serious Adverse Events
	Cabotegravir Oral 30 mg		Cabotegravir IM 600 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/19 (0%)		2/17 (11.8%)
Eye disorders
Pupils unequal	0/19 (0%)	0	1/17 (5.9%)	1
Gastrointestinal disorders
Dysphagia	0/19 (0%)	0	1/17 (5.9%)	1
Infections and infestations
Urinary tract infection	0/19 (0%)	0	1/17 (5.9%)	1
Nervous system disorders
Aphasia	0/19 (0%)	0	1/17 (5.9%)	1
Cerebral haemorrhage	0/19 (0%)	0	1/17 (5.9%)	1
Migraine with aura	0/19 (0%)	0	1/17 (5.9%)	1
Serotonin syndrome	0/19 (0%)	0	1/17 (5.9%)	1
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous	0/19 (0%)	0	1/17 (5.9%)	1
Psychiatric disorders
Post-traumatic stress disorder	0/19 (0%)	0	1/17 (5.9%)	1
Respiratory, thoracic and mediastinal disorders
Dyspnoea	0/19 (0%)	0	1/17 (5.9%)	1
Vascular disorders
Deep vein thrombosis	0/19 (0%)	0	1/17 (5.9%)	1
Other (Not Including Serious) Adverse Events
	Cabotegravir Oral 30 mg		Cabotegravir IM 600 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	10/19 (52.6%)		17/17 (100%)
Cardiac disorders
Palpitations	0/19 (0%)	0	2/17 (11.8%)	2
Gastrointestinal disorders
Diarrhoea	0/19 (0%)	0	1/17 (5.9%)	1
Dry mouth	0/19 (0%)	0	1/17 (5.9%)	1
Nausea	1/19 (5.3%)	1	0/17 (0%)	0
General disorders
Injection site pain	0/19 (0%)	0	15/17 (88.2%)	22
Fatigue	1/19 (5.3%)	1	1/17 (5.9%)	1
Injection site erythema	0/19 (0%)	0	2/17 (11.8%)	2
Pyrexia	0/19 (0%)	0	2/17 (11.8%)	2
Gait disturbance	0/19 (0%)	0	1/17 (5.9%)	1
Influenza like illness	0/19 (0%)	0	1/17 (5.9%)	1
Injection site induration	0/19 (0%)	0	1/17 (5.9%)	1
Injection site pruritus	0/19 (0%)	0	1/17 (5.9%)	1
Injection site reaction	0/19 (0%)	0	1/17 (5.9%)	1
Injection site swelling	0/19 (0%)	0	1/17 (5.9%)	1
Thirst	0/19 (0%)	0	1/17 (5.9%)	1
Infections and infestations
Gastroenteritis viral	3/19 (15.8%)	3	0/17 (0%)	0
Bacterial vaginosis	1/19 (5.3%)	1	0/17 (0%)	0
Influenza	0/19 (0%)	0	1/17 (5.9%)	1
Nasopharyngitis	0/19 (0%)	0	1/17 (5.9%)	1
Oral herpes	0/19 (0%)	0	1/17 (5.9%)	1
Upper respiratory tract infection	0/19 (0%)	0	1/17 (5.9%)	1
Viral upper respiratory tract infection	0/19 (0%)	0	1/17 (5.9%)	1
Injury, poisoning and procedural complications
Arthropod sting	1/19 (5.3%)	1	0/17 (0%)	0
Post procedural discharge	1/19 (5.3%)	1	0/17 (0%)	0
Investigations
Blood glucose increased	2/19 (10.5%)	2	0/17 (0%)	0
Haemoglobin decreased	0/19 (0%)	0	1/17 (5.9%)	1
Musculoskeletal and connective tissue disorders
Myalgia	0/19 (0%)	0	1/17 (5.9%)	1
Nervous system disorders
Headache	0/19 (0%)	0	2/17 (11.8%)	2
Lethargy	0/19 (0%)	0	1/17 (5.9%)	1
Syncope	1/19 (5.3%)	1	0/17 (0%)	0
Psychiatric disorders
Depression	0/19 (0%)	0	2/17 (11.8%)	2
Insomnia	0/19 (0%)	0	2/17 (11.8%)	2
Renal and urinary disorders
Dysuria	0/19 (0%)	0	1/17 (5.9%)	1
Pollakiuria	0/19 (0%)	0	1/17 (5.9%)	1
Reproductive system and breast disorders
Pelvic floor muscle weakness	0/19 (0%)	0	1/17 (5.9%)	1
Prostatitis	0/19 (0%)	0	1/17 (5.9%)	1
Testicular pain	0/19 (0%)	0	1/17 (5.9%)	1
Respiratory, thoracic and mediastinal disorders
Cough	1/19 (5.3%)	1	0/17 (0%)	0
Nasal congestion	0/19 (0%)	0	1/17 (5.9%)	1
Rhinorrhoea	1/19 (5.3%)	1	0/17 (0%)	0
Skin and subcutaneous tissue disorders
Dry skin	0/19 (0%)	0	1/17 (5.9%)	1
Ecchymosis	1/19 (5.3%)	1	0/17 (0%)	0
Eczema	1/19 (5.3%)	1	0/17 (0%)	0
Pruritus	0/19 (0%)	0	1/17 (5.9%)	1

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.